The global market for Myasthenia Gravis Treatment was valued at US$ 1903 million in the year 2024 and is projected to reach a revised size of US$ 2939 million by 2031, growing at a CAGR of 6.5% during the forecast period.

Myasthenia Gravis Treatment Market

Drug therapy for MG includes: (1) acetylcholinesterase inhibitors, (2) immunosuppressants, (3) immunomodulators. Introduce and gradually increase options based on international guidelines and the clinical and immunological characteristics of patients. Surgical treatments include (1) thymectomy, (2) median sternotomy and video-assisted thoracoscopic surgery, etc.

The major factors driving the market growth are increasing prevalence of myasthenia gravis, awareness for early diagnosis of myasthenia gravis, and adoption of new treatment options for myasthenia gravis. Rising prevalence of myasthenia gravis globally is one of the major drivers for the growth of the myasthenia gravis treatment market. For example, according to the Myasthenia Gravis Foundation of America, about 20 out of every 100,000 people in the United States have myasthenia gravis, and the disease is more common in women than men. Furthermore, the incidence of myasthenia gravis is increasing worldwide.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Myasthenia Gravis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myasthenia Gravis Treatment.

The Myasthenia Gravis Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Myasthenia Gravis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Myasthenia Gravis Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Myasthenia Gravis Treatment Market Report

Report Metric	Details
Report Name	Myasthenia Gravis Treatment Market
Accounted market size in year	US$ 1903 million
Forecasted market size in 2031	US$ 2939 million
CAGR	6.5%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Monoclonal Antibodies Intravenous Immunoglobulin Other
Segment by Application	Hospital Specialist Clinic Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Amneal Pharmaceuticals, Inc., Astellas Pharma, Inc., Avadel Pharmaceuticals PLC, Bausch Health Companies Inc., CSL Behring, CuraVac, Inc., Argenx SE, GlaxoSmithKline plc, Immunovant, Inc., Mitsubishi Tanabe Pharma Corp., Novartis AG, Takeda Pharmaceutical Co., Ltd., UCB Pharma, AstraZeneca, F. Hoffmann-La Roche Ltd
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Myasthenia Gravis Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Myasthenia Gravis Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Myasthenia Gravis Treatment Market growing?

Ans: The Myasthenia Gravis Treatment Market witnessing a CAGR of 6.5% during the forecast period 2025-2031.

What is the Myasthenia Gravis Treatment Market size in 2031?

Ans: The Myasthenia Gravis Treatment Market size in 2031 will be US$ 2939 million.

Who are the main players in the Myasthenia Gravis Treatment Market report?

Ans: The main players in the Myasthenia Gravis Treatment Market are Amneal Pharmaceuticals, Inc., Astellas Pharma, Inc., Avadel Pharmaceuticals PLC, Bausch Health Companies Inc., CSL Behring, CuraVac, Inc., Argenx SE, GlaxoSmithKline plc, Immunovant, Inc., Mitsubishi Tanabe Pharma Corp., Novartis AG, Takeda Pharmaceutical Co., Ltd., UCB Pharma, AstraZeneca, F. Hoffmann-La Roche Ltd

What are the Application segmentation covered in the Myasthenia Gravis Treatment Market report?

Ans: The Applications covered in the Myasthenia Gravis Treatment Market report are Hospital, Specialist Clinic, Other

What are the Type segmentation covered in the Myasthenia Gravis Treatment Market report?

Ans: The Types covered in the Myasthenia Gravis Treatment Market report are Monoclonal Antibodies, Intravenous Immunoglobulin, Other

1 Myasthenia Gravis Treatment Market Overview

1.1 Product Definition

1.2 Myasthenia Gravis Treatment by Type

1.2.1 Global Myasthenia Gravis Treatment Market Value Comparison by Type (2024 VS 2031)

1.2.2 Monoclonal Antibodies

1.2.3 Intravenous Immunoglobulin

1.2.4 Other

1.3 Myasthenia Gravis Treatment by Application

1.3.1 Global Myasthenia Gravis Treatment Market Value by Application (2024 VS 2031)

1.3.2 Hospital

1.3.3 Specialist Clinic

1.3.4 Other

1.4 Global Myasthenia Gravis Treatment Market Size Estimates and Forecasts

1.4.1 Global Myasthenia Gravis Treatment Revenue 2020-2031

1.4.2 Global Myasthenia Gravis Treatment Sales 2020-2031

1.4.3 Global Myasthenia Gravis Treatment Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Myasthenia Gravis Treatment Market Competition by Manufacturers

2.1 Global Myasthenia Gravis Treatment Sales Market Share by Manufacturers (2020-2025)

2.2 Global Myasthenia Gravis Treatment Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Myasthenia Gravis Treatment Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Myasthenia Gravis Treatment, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Myasthenia Gravis Treatment, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Myasthenia Gravis Treatment, Product Type & Application

2.7 Global Key Manufacturers of Myasthenia Gravis Treatment, Date of Enter into This Industry

2.8 Global Myasthenia Gravis Treatment Market Competitive Situation and Trends

2.8.1 Global Myasthenia Gravis Treatment Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Myasthenia Gravis Treatment Players Market Share by Revenue

2.8.3 Global Myasthenia Gravis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Myasthenia Gravis Treatment Market Scenario by Region

3.1 Global Myasthenia Gravis Treatment Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Myasthenia Gravis Treatment Sales by Region: 2020-2031

3.2.1 Global Myasthenia Gravis Treatment Sales by Region: 2020-2025

3.2.2 Global Myasthenia Gravis Treatment Sales by Region: 2026-2031

3.3 Global Myasthenia Gravis Treatment Revenue by Region: 2020-2031

3.3.1 Global Myasthenia Gravis Treatment Revenue by Region: 2020-2025

3.3.2 Global Myasthenia Gravis Treatment Revenue by Region: 2026-2031

3.4 North America Myasthenia Gravis Treatment Market Facts & Figures by Country

3.4.1 North America Myasthenia Gravis Treatment Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Myasthenia Gravis Treatment Sales by Country (2020-2031)

3.4.3 North America Myasthenia Gravis Treatment Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Myasthenia Gravis Treatment Market Facts & Figures by Country

3.5.1 Europe Myasthenia Gravis Treatment Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Myasthenia Gravis Treatment Sales by Country (2020-2031)

3.5.3 Europe Myasthenia Gravis Treatment Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Myasthenia Gravis Treatment Market Facts & Figures by Region

3.6.1 Asia Pacific Myasthenia Gravis Treatment Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Myasthenia Gravis Treatment Sales by Region (2020-2031)

3.6.3 Asia Pacific Myasthenia Gravis Treatment Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Myasthenia Gravis Treatment Market Facts & Figures by Country

3.7.1 Latin America Myasthenia Gravis Treatment Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Myasthenia Gravis Treatment Sales by Country (2020-2031)

3.7.3 Latin America Myasthenia Gravis Treatment Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Myasthenia Gravis Treatment Market Facts & Figures by Country

3.8.1 Middle East and Africa Myasthenia Gravis Treatment Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Myasthenia Gravis Treatment Sales by Country (2020-2031)

3.8.3 Middle East and Africa Myasthenia Gravis Treatment Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Myasthenia Gravis Treatment Sales by Type (2020-2031)

4.1.1 Global Myasthenia Gravis Treatment Sales by Type (2020-2025)

4.1.2 Global Myasthenia Gravis Treatment Sales by Type (2026-2031)

4.1.3 Global Myasthenia Gravis Treatment Sales Market Share by Type (2020-2031)

4.2 Global Myasthenia Gravis Treatment Revenue by Type (2020-2031)

4.2.1 Global Myasthenia Gravis Treatment Revenue by Type (2020-2025)

4.2.2 Global Myasthenia Gravis Treatment Revenue by Type (2026-2031)

4.2.3 Global Myasthenia Gravis Treatment Revenue Market Share by Type (2020-2031)

4.3 Global Myasthenia Gravis Treatment Price by Type (2020-2031)

5 Segment by Application

5.1 Global Myasthenia Gravis Treatment Sales by Application (2020-2031)

5.1.1 Global Myasthenia Gravis Treatment Sales by Application (2020-2025)

5.1.2 Global Myasthenia Gravis Treatment Sales by Application (2026-2031)

5.1.3 Global Myasthenia Gravis Treatment Sales Market Share by Application (2020-2031)

5.2 Global Myasthenia Gravis Treatment Revenue by Application (2020-2031)

5.2.1 Global Myasthenia Gravis Treatment Revenue by Application (2020-2025)

5.2.2 Global Myasthenia Gravis Treatment Revenue by Application (2026-2031)

5.2.3 Global Myasthenia Gravis Treatment Revenue Market Share by Application (2020-2031)

5.3 Global Myasthenia Gravis Treatment Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Amneal Pharmaceuticals, Inc.

6.1.1 Amneal Pharmaceuticals, Inc. Company Information

6.1.2 Amneal Pharmaceuticals, Inc. Description and Business Overview

6.1.3 Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Product Portfolio

6.1.5 Amneal Pharmaceuticals, Inc. Recent Developments/Updates

6.2 Astellas Pharma, Inc.

6.2.1 Astellas Pharma, Inc. Company Information

6.2.2 Astellas Pharma, Inc. Description and Business Overview

6.2.3 Astellas Pharma, Inc. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Astellas Pharma, Inc. Myasthenia Gravis Treatment Product Portfolio

6.2.5 Astellas Pharma, Inc. Recent Developments/Updates

6.3 Avadel Pharmaceuticals PLC

6.3.1 Avadel Pharmaceuticals PLC Company Information

6.3.2 Avadel Pharmaceuticals PLC Description and Business Overview

6.3.3 Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Product Portfolio

6.3.5 Avadel Pharmaceuticals PLC Recent Developments/Updates

6.4 Bausch Health Companies Inc.

6.4.1 Bausch Health Companies Inc. Company Information

6.4.2 Bausch Health Companies Inc. Description and Business Overview

6.4.3 Bausch Health Companies Inc. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Bausch Health Companies Inc. Myasthenia Gravis Treatment Product Portfolio

6.4.5 Bausch Health Companies Inc. Recent Developments/Updates

6.5 CSL Behring

6.5.1 CSL Behring Company Information

6.5.2 CSL Behring Description and Business Overview

6.5.3 CSL Behring Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2020-2025)

6.5.4 CSL Behring Myasthenia Gravis Treatment Product Portfolio

6.5.5 CSL Behring Recent Developments/Updates

6.6 CuraVac, Inc.

6.6.1 CuraVac, Inc. Company Information

6.6.2 CuraVac, Inc. Description and Business Overview

6.6.3 CuraVac, Inc. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2020-2025)

6.6.4 CuraVac, Inc. Myasthenia Gravis Treatment Product Portfolio

6.6.5 CuraVac, Inc. Recent Developments/Updates

6.7 Argenx SE

6.7.1 Argenx SE Company Information

6.7.2 Argenx SE Description and Business Overview

6.7.3 Argenx SE Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Argenx SE Myasthenia Gravis Treatment Product Portfolio

6.7.5 Argenx SE Recent Developments/Updates

6.8 GlaxoSmithKline plc

6.8.1 GlaxoSmithKline plc Company Information

6.8.2 GlaxoSmithKline plc Description and Business Overview

6.8.3 GlaxoSmithKline plc Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2020-2025)

6.8.4 GlaxoSmithKline plc Myasthenia Gravis Treatment Product Portfolio

6.8.5 GlaxoSmithKline plc Recent Developments/Updates

6.9 Immunovant, Inc.

6.9.1 Immunovant, Inc. Company Information

6.9.2 Immunovant, Inc. Description and Business Overview

6.9.3 Immunovant, Inc. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Immunovant, Inc. Myasthenia Gravis Treatment Product Portfolio

6.9.5 Immunovant, Inc. Recent Developments/Updates

6.10 Mitsubishi Tanabe Pharma Corp.

6.10.1 Mitsubishi Tanabe Pharma Corp. Company Information

6.10.2 Mitsubishi Tanabe Pharma Corp. Description and Business Overview

6.10.3 Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Product Portfolio

6.10.5 Mitsubishi Tanabe Pharma Corp. Recent Developments/Updates

6.11 Novartis AG

6.11.1 Novartis AG Company Information

6.11.2 Novartis AG Description and Business Overview

6.11.3 Novartis AG Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Novartis AG Myasthenia Gravis Treatment Product Portfolio

6.11.5 Novartis AG Recent Developments/Updates

6.12 Takeda Pharmaceutical Co., Ltd.

6.12.1 Takeda Pharmaceutical Co., Ltd. Company Information

6.12.2 Takeda Pharmaceutical Co., Ltd. Description and Business Overview

6.12.3 Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2020-2025)

6.12.4 Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Product Portfolio

6.12.5 Takeda Pharmaceutical Co., Ltd. Recent Developments/Updates

6.13 UCB Pharma

6.13.1 UCB Pharma Company Information

6.13.2 UCB Pharma Description and Business Overview

6.13.3 UCB Pharma Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2020-2025)

6.13.4 UCB Pharma Myasthenia Gravis Treatment Product Portfolio

6.13.5 UCB Pharma Recent Developments/Updates

6.14 AstraZeneca

6.14.1 AstraZeneca Company Information

6.14.2 AstraZeneca Description and Business Overview

6.14.3 AstraZeneca Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2020-2025)

6.14.4 AstraZeneca Myasthenia Gravis Treatment Product Portfolio

6.14.5 AstraZeneca Recent Developments/Updates

6.15 F. Hoffmann-La Roche Ltd

6.15.1 F. Hoffmann-La Roche Ltd Company Information

6.15.2 F. Hoffmann-La Roche Ltd Description and Business Overview

6.15.3 F. Hoffmann-La Roche Ltd Myasthenia Gravis Treatment Sales, Revenue and Gross Margin (2020-2025)

6.15.4 F. Hoffmann-La Roche Ltd Myasthenia Gravis Treatment Product Portfolio

6.15.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Myasthenia Gravis Treatment Industry Chain Analysis

7.2 Myasthenia Gravis Treatment Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Myasthenia Gravis Treatment Production Mode & Process Analysis

7.4 Myasthenia Gravis Treatment Sales and Marketing

7.4.1 Myasthenia Gravis Treatment Sales Channels

7.4.2 Myasthenia Gravis Treatment Distributors

7.5 Myasthenia Gravis Treatment Customer Analysis

8 Myasthenia Gravis Treatment Market Dynamics

8.1 Myasthenia Gravis Treatment Industry Trends

8.2 Myasthenia Gravis Treatment Market Drivers

8.3 Myasthenia Gravis Treatment Market Challenges

8.4 Myasthenia Gravis Treatment Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Avadel Pharmaceuticals plc.

Bausch Health Companies Inc.

GlaxoSmithKline PLC

Novartis

F Hoffmann La Roche Ltd

Amneal Pharmaceuticals, Inc.

Mitsubishi Tanabe Pharma Corp

Takeda Pharmaceutical Co Ltd

UCB Pharma

Astrazeneca plc

List of Tables

Table 1. Global Myasthenia Gravis Treatment Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Myasthenia Gravis Treatment Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Myasthenia Gravis Treatment Market Competitive Situation by Manufacturers in 2024

Table 4. Global Myasthenia Gravis Treatment Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Myasthenia Gravis Treatment Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Myasthenia Gravis Treatment Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Myasthenia Gravis Treatment Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Myasthenia Gravis Treatment Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Myasthenia Gravis Treatment, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Myasthenia Gravis Treatment, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Myasthenia Gravis Treatment, Product Type & Application

Table 12. Global Key Manufacturers of Myasthenia Gravis Treatment, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Myasthenia Gravis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myasthenia Gravis Treatment as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Myasthenia Gravis Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Myasthenia Gravis Treatment Sales by Region (2020-2025) & (K Units)

Table 18. Global Myasthenia Gravis Treatment Sales Market Share by Region (2020-2025)

Table 19. Global Myasthenia Gravis Treatment Sales by Region (2026-2031) & (K Units)

Table 20. Global Myasthenia Gravis Treatment Sales Market Share by Region (2026-2031)

Table 21. Global Myasthenia Gravis Treatment Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Myasthenia Gravis Treatment Revenue Market Share by Region (2020-2025)

Table 23. Global Myasthenia Gravis Treatment Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Myasthenia Gravis Treatment Revenue Market Share by Region (2026-2031)

Table 25. North America Myasthenia Gravis Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Myasthenia Gravis Treatment Sales by Country (2020-2025) & (K Units)

Table 27. North America Myasthenia Gravis Treatment Sales by Country (2026-2031) & (K Units)

Table 28. North America Myasthenia Gravis Treatment Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Myasthenia Gravis Treatment Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Myasthenia Gravis Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Myasthenia Gravis Treatment Sales by Country (2020-2025) & (K Units)

Table 32. Europe Myasthenia Gravis Treatment Sales by Country (2026-2031) & (K Units)

Table 33. Europe Myasthenia Gravis Treatment Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Myasthenia Gravis Treatment Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Myasthenia Gravis Treatment Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Myasthenia Gravis Treatment Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Myasthenia Gravis Treatment Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Myasthenia Gravis Treatment Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Myasthenia Gravis Treatment Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Myasthenia Gravis Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Myasthenia Gravis Treatment Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Myasthenia Gravis Treatment Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Myasthenia Gravis Treatment Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Myasthenia Gravis Treatment Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Myasthenia Gravis Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Myasthenia Gravis Treatment Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Myasthenia Gravis Treatment Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Myasthenia Gravis Treatment Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Myasthenia Gravis Treatment Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Myasthenia Gravis Treatment Sales (K Units) by Type (2020-2025)

Table 51. Global Myasthenia Gravis Treatment Sales (K Units) by Type (2026-2031)

Table 52. Global Myasthenia Gravis Treatment Sales Market Share by Type (2020-2025)

Table 53. Global Myasthenia Gravis Treatment Sales Market Share by Type (2026-2031)

Table 54. Global Myasthenia Gravis Treatment Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Myasthenia Gravis Treatment Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Myasthenia Gravis Treatment Revenue Market Share by Type (2020-2025)

Table 57. Global Myasthenia Gravis Treatment Revenue Market Share by Type (2026-2031)

Table 58. Global Myasthenia Gravis Treatment Price (US$/Unit) by Type (2020-2025)

Table 59. Global Myasthenia Gravis Treatment Price (US$/Unit) by Type (2026-2031)

Table 60. Global Myasthenia Gravis Treatment Sales (K Units) by Application (2020-2025)

Table 61. Global Myasthenia Gravis Treatment Sales (K Units) by Application (2026-2031)

Table 62. Global Myasthenia Gravis Treatment Sales Market Share by Application (2020-2025)

Table 63. Global Myasthenia Gravis Treatment Sales Market Share by Application (2026-2031)

Table 64. Global Myasthenia Gravis Treatment Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Myasthenia Gravis Treatment Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Myasthenia Gravis Treatment Revenue Market Share by Application (2020-2025)

Table 67. Global Myasthenia Gravis Treatment Revenue Market Share by Application (2026-2031)

Table 68. Global Myasthenia Gravis Treatment Price (US$/Unit) by Application (2020-2025)

Table 69. Global Myasthenia Gravis Treatment Price (US$/Unit) by Application (2026-2031)

Table 70. Amneal Pharmaceuticals, Inc. Company Information

Table 71. Amneal Pharmaceuticals, Inc. Description and Business Overview

Table 72. Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Amneal Pharmaceuticals, Inc. Myasthenia Gravis Treatment Product

Table 74. Amneal Pharmaceuticals, Inc. Recent Developments/Updates

Table 75. Astellas Pharma, Inc. Company Information

Table 76. Astellas Pharma, Inc. Description and Business Overview

Table 77. Astellas Pharma, Inc. Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Astellas Pharma, Inc. Myasthenia Gravis Treatment Product

Table 79. Astellas Pharma, Inc. Recent Developments/Updates

Table 80. Avadel Pharmaceuticals PLC Company Information

Table 81. Avadel Pharmaceuticals PLC Description and Business Overview

Table 82. Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. Avadel Pharmaceuticals PLC Myasthenia Gravis Treatment Product

Table 84. Avadel Pharmaceuticals PLC Recent Developments/Updates

Table 85. Bausch Health Companies Inc. Company Information

Table 86. Bausch Health Companies Inc. Description and Business Overview

Table 87. Bausch Health Companies Inc. Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. Bausch Health Companies Inc. Myasthenia Gravis Treatment Product

Table 89. Bausch Health Companies Inc. Recent Developments/Updates

Table 90. CSL Behring Company Information

Table 91. CSL Behring Description and Business Overview

Table 92. CSL Behring Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. CSL Behring Myasthenia Gravis Treatment Product

Table 94. CSL Behring Recent Developments/Updates

Table 95. CuraVac, Inc. Company Information

Table 96. CuraVac, Inc. Description and Business Overview

Table 97. CuraVac, Inc. Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. CuraVac, Inc. Myasthenia Gravis Treatment Product

Table 99. CuraVac, Inc. Recent Developments/Updates

Table 100. Argenx SE Company Information

Table 101. Argenx SE Description and Business Overview

Table 102. Argenx SE Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. Argenx SE Myasthenia Gravis Treatment Product

Table 104. Argenx SE Recent Developments/Updates

Table 105. GlaxoSmithKline plc Company Information

Table 106. GlaxoSmithKline plc Description and Business Overview

Table 107. GlaxoSmithKline plc Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 108. GlaxoSmithKline plc Myasthenia Gravis Treatment Product

Table 109. GlaxoSmithKline plc Recent Developments/Updates

Table 110. Immunovant, Inc. Company Information

Table 111. Immunovant, Inc. Description and Business Overview

Table 112. Immunovant, Inc. Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 113. Immunovant, Inc. Myasthenia Gravis Treatment Product

Table 114. Immunovant, Inc. Recent Developments/Updates

Table 115. Mitsubishi Tanabe Pharma Corp. Company Information

Table 116. Mitsubishi Tanabe Pharma Corp. Description and Business Overview

Table 117. Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 118. Mitsubishi Tanabe Pharma Corp. Myasthenia Gravis Treatment Product

Table 119. Mitsubishi Tanabe Pharma Corp. Recent Developments/Updates

Table 120. Novartis AG Company Information

Table 121. Novartis AG Description and Business Overview

Table 122. Novartis AG Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 123. Novartis AG Myasthenia Gravis Treatment Product

Table 124. Novartis AG Recent Developments/Updates

Table 125. Takeda Pharmaceutical Co., Ltd. Company Information

Table 126. Takeda Pharmaceutical Co., Ltd. Description and Business Overview

Table 127. Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 128. Takeda Pharmaceutical Co., Ltd. Myasthenia Gravis Treatment Product

Table 129. Takeda Pharmaceutical Co., Ltd. Recent Developments/Updates

Table 130. UCB Pharma Company Information

Table 131. UCB Pharma Description and Business Overview

Table 132. UCB Pharma Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 133. UCB Pharma Myasthenia Gravis Treatment Product

Table 134. UCB Pharma Recent Developments/Updates

Table 135. AstraZeneca Company Information

Table 136. AstraZeneca Description and Business Overview

Table 137. AstraZeneca Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 138. AstraZeneca Myasthenia Gravis Treatment Product

Table 139. AstraZeneca Recent Developments/Updates

Table 140. F. Hoffmann-La Roche Ltd Company Information

Table 141. F. Hoffmann-La Roche Ltd Description and Business Overview

Table 142. F. Hoffmann-La Roche Ltd Myasthenia Gravis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 143. F. Hoffmann-La Roche Ltd Myasthenia Gravis Treatment Product

Table 144. F. Hoffmann-La Roche Ltd Recent Developments/Updates

Table 145. Key Raw Materials Lists

Table 146. Raw Materials Key Suppliers Lists

Table 147. Myasthenia Gravis Treatment Distributors List

Table 148. Myasthenia Gravis Treatment Customers List

Table 149. Myasthenia Gravis Treatment Market Trends

Table 150. Myasthenia Gravis Treatment Market Drivers

Table 151. Myasthenia Gravis Treatment Market Challenges

Table 152. Myasthenia Gravis Treatment Market Restraints

Table 153. Research Programs/Design for This Report

Table 154. Key Data Information from Secondary Sources

Table 155. Key Data Information from Primary Sources

Table 156. Authors List of This Report

List of Figures

Figure 1. Product Picture of Myasthenia Gravis Treatment

Figure 2. Global Myasthenia Gravis Treatment Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Myasthenia Gravis Treatment Market Share by Type: 2024 & 2031

Figure 4. Monoclonal Antibodies Product Picture

Figure 5. Intravenous Immunoglobulin Product Picture

Figure 6. Other Product Picture

Figure 7. Global Myasthenia Gravis Treatment Market Value by Application (2020-2031) & (US$ Million)

Figure 8. Global Myasthenia Gravis Treatment Market Share by Application: 2024 & 2031

Figure 9. Hospital

Figure 10. Specialist Clinic

Figure 11. Other

Figure 12. Global Myasthenia Gravis Treatment Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Myasthenia Gravis Treatment Market Size (2020-2031) & (US$ Million)

Figure 14. Global Myasthenia Gravis Treatment Sales (2020-2031) & (K Units)

Figure 15. Global Myasthenia Gravis Treatment Average Price (US$/Unit) & (2020-2031)

Figure 16. Myasthenia Gravis Treatment Report Years Considered

Figure 17. Myasthenia Gravis Treatment Sales Share by Manufacturers in 2024

Figure 18. Global Myasthenia Gravis Treatment Revenue Share by Manufacturers in 2024

Figure 19. Global 5 and 10 Largest Myasthenia Gravis Treatment Players: Market Share by Revenue in Myasthenia Gravis Treatment in 2024

Figure 20. Myasthenia Gravis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 21. Global Myasthenia Gravis Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 22. North America Myasthenia Gravis Treatment Sales Market Share by Country (2020-2031)

Figure 23. North America Myasthenia Gravis Treatment Revenue Market Share by Country (2020-2031)

Figure 24. United States Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Canada Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Europe Myasthenia Gravis Treatment Sales Market Share by Country (2020-2031)

Figure 27. Europe Myasthenia Gravis Treatment Revenue Market Share by Country (2020-2031)

Figure 28. Germany Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. France Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. U.K. Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Italy Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Russia Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Asia Pacific Myasthenia Gravis Treatment Sales Market Share by Region (2020-2031)

Figure 34. Asia Pacific Myasthenia Gravis Treatment Revenue Market Share by Region (2020-2031)

Figure 35. China Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Japan Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. South Korea Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. India Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Australia Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. China Taiwan Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Indonesia Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Thailand Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Malaysia Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Latin America Myasthenia Gravis Treatment Sales Market Share by Country (2020-2031)

Figure 45. Latin America Myasthenia Gravis Treatment Revenue Market Share by Country (2020-2031)

Figure 46. Mexico Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Brazil Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Argentina Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Middle East and Africa Myasthenia Gravis Treatment Sales Market Share by Country (2020-2031)

Figure 50. Middle East and Africa Myasthenia Gravis Treatment Revenue Market Share by Country (2020-2031)

Figure 51. Turkey Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Saudi Arabia Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. UAE Myasthenia Gravis Treatment Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Global Sales Market Share of Myasthenia Gravis Treatment by Type (2020-2031)

Figure 55. Global Revenue Market Share of Myasthenia Gravis Treatment by Type (2020-2031)

Figure 56. Global Myasthenia Gravis Treatment Price (US$/Unit) by Type (2020-2031)

Figure 57. Global Sales Market Share of Myasthenia Gravis Treatment by Application (2020-2031)

Figure 58. Global Revenue Market Share of Myasthenia Gravis Treatment by Application (2020-2031)

Figure 59. Global Myasthenia Gravis Treatment Price (US$/Unit) by Application (2020-2031)

Figure 60. Myasthenia Gravis Treatment Value Chain

Figure 61. Channels of Distribution (Direct Vs Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: MICR-Othe-3W5

Sun Mar 09 09:29:03 UTC 2025

$1400

Single User

Add to Cart

Global Multi-Person EEG Acquisition Equipment Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-11M19145

Mon Feb 17 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Neuronal Markers Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-24M10267

Mon Feb 17 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Anti-Vascular Endothelial Growth Factor Therapeutic Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-39J14324

Thu Feb 13 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Myasthenia Gravis Treatment Market Research Report 2025

Published Date: February 2025

Report Code: QYRE-Auto-2X13462

Global Myasthenia Gravis Treatment Market Research Report 2025

FEATURED COMPANIES

Myasthenia Gravis Treatment Market Size

Myasthenia Gravis Treatment Market

Report Scope

Scope of Myasthenia Gravis Treatment Market Report

Core Chapters

FAQ for this report

How fast is Myasthenia Gravis Treatment Market growing?

What is the Myasthenia Gravis Treatment Market size in 2031?

Who are the main players in the Myasthenia Gravis Treatment Market report?

What are the Application segmentation covered in the Myasthenia Gravis Treatment Market report?

What are the Type segmentation covered in the Myasthenia Gravis Treatment Market report?

FEATURED COMPANIES

RELATED REPORTS

$1400

Single User

$5800

Enterprise User

$5800

Enterprise User

$5800

Enterprise User